ALK and non-small cell lung carcinoma: The main druggable genetic alterations in non-small cell lung cancer involved EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma viral oncogene homolog), ALK (anaplastic lymphoma kinase), BRAF (V-raf murine sarcoma oncogene homolog B1), and ROS1 (c-ros oncogene 1) genes.